A clinical study found an at-home test based on the DNA found in spit samples could detect cases of prostate cancer that would otherwise slip past a standard blood draw.

As Keytruda’s 2028 patent cliff looms large, Merck & Co.’s renewed R&D oncology strategy focuses on three strategies. One of those prongs is improving immune responses, a pillar that stars Moderna-shared cancer vaccine mRNA-4157.

Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is back with a new cut showing 6% weight loss in a phase 2a study.

Trial software provider ConcertAI is partnering with Nvidia to develop new clinical simulations that inform future AI products for clinical trials, the company announced May 31 at the American Society of Cancer Oncology’s annual meeting.

Arrowhead Pharmaceuticals’ RNA interference (RNAi) therapeutic lowered triglycerides in patients with a rare metabolic disease that prevents the body from breaking down fats during a phase 3 trial.

Purple Biotech hopes its lead asset against metastatic pancreatic cancer will one day show its true colors as a potential first-in-class drug in a larger study—but, for now, it has preliminary, midstage trial results demonstrating measurable gains in overall survival.

Brain-computer interface startup Precision Neuroscience said it has claimed the world record for the number of electrodes used to detect a person’s thoughts—quadrupling the number used to read signals in Neuralink’s implant.

A new antibiotic based on drugs developed by AstraZeneca can kill off dangerous bacteria that cause sepsis and pneumonia without harming healthy gut microbes, research in mice shows. If further developed, drugs like it eventually could overcome a major downside to some antibiotics that is linked to serious complications.

We can now envision the oasis that Ionis Pharmaceuticals saw with its hereditary angioedema data.

Ultragenyx is gearing up to take its glycogen storage disease (GSD) treatment to regulators next year after the gene therapy helped patients reduce their intake of cornstarch, which is currently used to treat the disease, in a phase 3 trial.